In the first half of 2012, the company achieved sustained and steady growth in its business performance, achieving total operating revenue of 261,559,751.90 yuan, an increase of 26.41% over the same period of the previous year; and operating profit of 39,955,833.35 yuan, an increase of 50.65% over the same period of the previous year. The net profit of the company's owners was 38,096,826.26 yuan, an increase of 22.57% over the same period of last year.
In terms of marketing, based on the requirements of specialization and scale, the company has continuously improved the operational efficiency of the marketing system, strengthened the execution ability of the marketing team, and effectively expanded the fields of application and emerging technologies and products by deepening the performance assessment and incentive mechanisms. The market, in order to maintain the profitability of the product, led to a steady increase in sales, while marketing costs were effectively controlled.
During the reporting period, sales of instrument product lines, pathological product lines, TRF product lines, immune product lines, and public product lines grew rapidly while maintaining the steady growth of the nucleic acid diagnostic reagent market (PCR products). At the same time, the market development of independent laboratories continued to show a steady growth during the reporting period.
During the reporting period, the company received a total of 7 (first-time) medical device registration certificates issued by the State Food and Drug Administration: "Fever with thrombocytopenia syndrome Bunia virus nucleic acid quantitative detection kit (PCR-fluorescent probe method)" , "Human Immunodeficiency Virus Type 1 (HIV-1) Nucleic Acid Quantitative Detection Kit (PCR-Fluorescence Probe Method)", "Hepatitis B Virus Nucleic Acid Quantitative Detection Kit (PCR-Fluorescence Probe Method)", "Bladder Cancer cell chromosomal and genetic abnormality detection kit (fluorescence in situ hybridization method), "HER-2/neu gene detection kit (fluorescence in situ hybridization method)", "hepatitis C virus nucleic acid quantitative detection kit (PCR- Fluorescence Probe Method), Hepatitis C Virus Genotype Detection Kit (PCR-Reverse Dot Hybridization).
At the same time, Zhongshan Subsidiary Co., Ltd., a subsidiary company of the company, obtained 4 medical equipment registration certificates issued by the State Food and Drug Administration (the first time): Rapid Detection of Malignancy (Immunochromatography) and EB Virus Capsid Antigen (VCA) IgA Antibody Detection Kit (Enzyme-linked Immunosorbent Assay), "EB Virus Nucleoantigen 1 (NA1) IgA Antibody Assay Kit (Enzyme Immunoassay)", "EB Virus Zta Protein IgA Antibody Assay Kit ( law)".
During the reporting period, the company was awarded the Standardization Good Behavior Certificate issued by the Guangdong Provincial Bureau of Quality and Technical Supervision, and the Guangdong Securities Regulatory Bureau determined that the evaluation category of our 2012 classification evaluation results was Class A.
In terms of marketing, based on the requirements of specialization and scale, the company has continuously improved the operational efficiency of the marketing system, strengthened the execution ability of the marketing team, and effectively expanded the fields of application and emerging technologies and products by deepening the performance assessment and incentive mechanisms. The market, in order to maintain the profitability of the product, led to a steady increase in sales, while marketing costs were effectively controlled.
During the reporting period, sales of instrument product lines, pathological product lines, TRF product lines, immune product lines, and public product lines grew rapidly while maintaining the steady growth of the nucleic acid diagnostic reagent market (PCR products). At the same time, the market development of independent laboratories continued to show a steady growth during the reporting period.
During the reporting period, the company received a total of 7 (first-time) medical device registration certificates issued by the State Food and Drug Administration: "Fever with thrombocytopenia syndrome Bunia virus nucleic acid quantitative detection kit (PCR-fluorescent probe method)" , "Human Immunodeficiency Virus Type 1 (HIV-1) Nucleic Acid Quantitative Detection Kit (PCR-Fluorescence Probe Method)", "Hepatitis B Virus Nucleic Acid Quantitative Detection Kit (PCR-Fluorescence Probe Method)", "Bladder Cancer cell chromosomal and genetic abnormality detection kit (fluorescence in situ hybridization method), "HER-2/neu gene detection kit (fluorescence in situ hybridization method)", "hepatitis C virus nucleic acid quantitative detection kit (PCR- Fluorescence Probe Method), Hepatitis C Virus Genotype Detection Kit (PCR-Reverse Dot Hybridization).
At the same time, Zhongshan Subsidiary Co., Ltd., a subsidiary company of the company, obtained 4 medical equipment registration certificates issued by the State Food and Drug Administration (the first time): Rapid Detection of Malignancy (Immunochromatography) and EB Virus Capsid Antigen (VCA) IgA Antibody Detection Kit (Enzyme-linked Immunosorbent Assay), "EB Virus Nucleoantigen 1 (NA1) IgA Antibody Assay Kit (Enzyme Immunoassay)", "EB Virus Zta Protein IgA Antibody Assay Kit ( law)".
During the reporting period, the company was awarded the Standardization Good Behavior Certificate issued by the Guangdong Provincial Bureau of Quality and Technical Supervision, and the Guangdong Securities Regulatory Bureau determined that the evaluation category of our 2012 classification evaluation results was Class A.
Steel Wheelchair can be divided into economical, obese, heavy steel wheelchair, it has,Powder coating steel frame, Detachable footrest, fixed or flip-up armrest, solid cator,pneumatic rear wheel.
Steel Portable Wheelchai,Medical Folding Steel Wheelchair,Lightweight Handicapped Steel Wheelchair,Folding Manual Steel Wheelchair
jinan Fangqi Sunshine education consulting CO.,LTD. , https://www.fzrehabmarket.com